Efficacy of MK615 for the treatment of patients with liver disorders

World Journal of Gastroenterology

Volumn 18, Issue 31, 2012, Pages 4118-4126

  Hokari, Atsushi ^a   Ishikawa, Tomohisa ^a   Tajiri, Hisao ^a   Matsuda, Takahide ^b   Ishii, Osamu ^b   Matsumoto, Nobuyuki ^b   Okuse, Chiaki ^b   Takahashi, Hideaki ^b   Kurihara, Takeshi ^c   Kawahara, Ko ichi ^d   Maruyama, Ikuro ^e   Zeniya, Mikio ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d OSAKA INSTITUTE OF TECHNOLOGY   (Japan)

^e KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Hepatitis C; Liver damage; MK615; Non alcoholic fatty liver disease; Prunus mume

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GALACTOSAMINE; INDOMETACIN; MISATOL ME; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; BLOOD SAMPLING; CELL INFILTRATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIVER; LIVER CELL; LIVER INJURY; LIVER NECROSIS; LIVER PROTECTION; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIMARY SCLEROSING CHOLANGITIS; RAT; TREATMENT DURATION; URINALYSIS;

EID: 84867705567     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i31.4118     Document Type: Article

References (47)

1. Miyazawa M, Utsunomiya H, Inada K, Yamada T, Okuno Y, Tanaka H, Tatematsu M. Inhibition of Helicobacter pylori motility by (+)-Syringaresinol from unripe Japanese apricot. Biol Pharm Bull 2006; 29: 172-173
2. Yamai H, Sawada N, Yoshida T, Seike J, Takizawa H, Kenzaki K, Miyoshi T, Kondo K, Bando Y, Ohnishi Y, Tangoku A. Triterpenes augment the inhibitory effects of anticancer drugs on growth of human esophageal carcinoma cells in vitro and suppress experimental metastasis in vivo. Int J Cancer 2009; 125: 952-960
3. Kawahara K, Hashiguchi T, Masuda K, Saniabadi AR, Kikuchi K, Tancharoen S, Ito T, Miura N, Morimoto Y, Biswas KK, Nawa Y, Meng X, Oyama Y, Takenouchi K, Shrestha B, Sameshima H, Shimizu T, Adachi T, Adachi M, Maruyama I. Mechanism of HMGB1 release inhibition from RAW264.7 cells by oleanolic acid in Prunus mume Sieb. et Zucc. Int J Mol Med 2009; 23: 615-620
4. Al-Jahdari WS, Sakurai H, Yoshida Y, Mobaraki A, Suzuki Y, Nakano T. MK615, a prospective anti-proliferative agent, enhances CD4/CD8 ratio after exposure to irradiation. Int J Radiat Biol 2011; 87: 81-90
5. Adachi M, Suzuki Y, Mizuta T, Osawa T, Adachi T, Osaka K, Suzuki K, Shiojima K, Arai Y, Masuda K, Uchiyama M, Oyamada T, Clerici M. The "Prunus mume Sieb. et Zucc" (Ume) is a Rich Natural Source of Novel Anti-Cancer Substance. Int J Food Prop 2007; 10: 375-384
6. Nakagawa A, Sawada T, Okada T, Ohsawa T, Adachi M, Kubota K. New antineoplastic agent, MK615, from UME (a Variety of) Japanese apricot inhibits growth of breast cancer cells in vitro. Breast J 2007; 13: 44-49
7. Okada T, Sawada T, Osawa T, Adachi M, Kubota K. A novel anti-cancer substance, MK615, from ume, a variety of Japanese apricot, inhibits growth of hepatocellular carcinoma cells by suppressing Aurora A kinase activity. Hepatogastroenterology 2007; 54: 1770-1774
8. Sakuraoka Y, Sawada T, Okada T, Shiraki T, Miura Y, Hiraishi K, Ohsawa T, Adachi M, Takino J, Takeuchi M, Kubota K. MK615 decreases RAGE expression and inhibits TAGEinduced proliferation in hepatocellular carcinoma cells. World J Gastroenterol 2010; 16: 5334-5341
9. Mori S, Sawada T, Okada T, Ohsawa T, Adachi M, Keiichi K. New anti-proliferative agent, MK615, from Japanese apricot "Prunus mume" induces striking autophagy in colon cancer cells in vitro. World J Gastroenterol 2007; 13: 6512-6517
10. Okada T, Sawada T, Osawa T, Adachi M, Kubota K. MK615 inhibits pancreatic cancer cell growth by dual inhibition of Aurora A and B kinases. World J Gastroenterol 2008; 14: 1378-1382
11. Matsushita S, Tada K, Kawahara K, Kawai K, Hashiguchi T, Maruyama I, Kanekura T. Advanced malignant melanoma responds to Prunus mume Sieb. Et Zucc (Ume) extract: Case report and in vitro study. Exp and Ther Med 2010; 1: 569-574
12. Morimoto Y, Kikuchi K, Ito T, Tokuda M, Matsuyama T, Noma S, Hashiguchi T, Torii M, Maruyama I, Kawahara K. MK615 attenuates Porphyromonas gingivalis lipopolysaccharide-induced pro-inflammatory cytokine release via MAPK inactivation in murine macrophage-like RAW264.7 cells. Biochem Biophys Res Commun 2009; 389: 90-94
13. Nishioka H, Kishioka T, Iida C, Fujii K, Ichi I, Kojo S. Activation of mitogen activated protein kinase (MAPK) during D-galactosamine intoxication in the rat liver. Bioorg Med Chem Lett 2006; 16: 3019-3022
14. Wen T, Wu ZM, Liu Y, Tan YF, Ren F, Wu H. Upregulation of heme oxygenase-1 with hemin prevents D-galactosamine and lipopolysaccharide-induced acute hepatic injury in rats. Toxicology 2007; 237: 184-193
15. Hoffmann F, Sass G, Zillies J, Zahler S, Tiegs G, Hartkorn A, Fuchs S, Wagner J, Winter G, Coester C, Gerbes AL, Vollmar AM. A novel technique for selective NF-kappaB inhibition in Kupffer cells: contrary effects in fulminant hepatitis and ischaemia-reperfusion. Gut 2009; 58: 1670-1678
16. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982
17. Fassio E. Hepatitis C and hepatocellular carcinoma. Ann Hepatol 2010; 9 Suppl: 119-122
18. Tarao K, Rino Y, Ohkawa S, Shimizu A, Tamai S, Miyakawa K, Aoki H, Imada T, Shindo K, Okamoto N, Totsuka S. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virusassociated cirrhosis. Cancer 1999; 86: 589-595
19. Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Hayashi K, Honda T, Kuzuya T. Influence of age, sex, and degree of liver fibrosis on the association between serum alanine aminotransferase levels and liver inflammation in patients with chronic hepatitis C. Dig Dis Sci 2004; 49: 295-299
20. Rino Y, Tarao K, Morinaga S, Ohkawa S, Miyakawa K, Hirokawa S, Masaki T, Tarao N, Yukawa N, Saeki H, Takanashi Y, Imada T. Reduction therapy of alanine aminotransferase levels prevent HCC development in patients with HCVassociated cirrhosis. Anticancer Res 2006; 26: 2221-2226
21. Kurokawa M, Hiramatsu N, Oze T, Mochizuki K, Yakushijin T, Kurashige N, Inoue Y, Igura T, Imanaka K, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Yoshihara H, Inoue A, Imai Y, Kato M, Kiso S, Kanto T, Takehara T, Kasahara A, Hayashi N. Effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis. Hepatol Res 2009; 39: 432-438
22. Nelson DR, Lim HL, Marousis CG, Fang JW, Davis GL, Shen L, Urdea MS, Kolberg JA, Lau JY. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci 1997; 42: 2487-2494
23. Gochee PA, Jonsson JR, Clouston AD, Pandeya N, Purdie DM, Powell EE. Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen I, tumor necrosis factor-alpha and cytochrome P450 2E1. J Gastroenterol Hepatol 2003; 18: 386-392
24. Malaguarnera M, Di Fazio I, Romeo MA, Restuccia S, Laurino A, Trovato BA. Elevation of interleukin 6 levels in patients with chronic hepatitis due to hepatitis C virus. J Gastroenterol 1997; 32: 211-215
25. Oyanagi Y, Takahashi T, Matsui S, Takahashi S, Boku S, Takahashi K, Furukawa K, Arai F, Asakura H. Enhanced expression of interleukin-6 in chronic hepatitis C. Liver 1999; 19: 464-472
26. Okada K, Shoda J, Taguchi K, Maher JM, Ishizaki K, Inoue Y, Ohtsuki M, Goto N, Takeda K, Utsunomiya H, Oda K, Warabi E, Ishii T, Osaka K, Hyodo I, Yamamoto M. Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxification, and antioxidative stress systems in mice. Am J Physiol Gastrointest Liver Physiol 2008; 295: G735-G747
27. Liu J, Wu Q, Lu YF, Pi J. New insights into generalized hepatoprotective effects of oleanolic acid: key roles of metallothionein and Nrf2 induction. Biochem Pharmacol 2008; 76: 922-928
28. Reisman SA, Aleksunes LM, Klaassen CD. Oleanolic acid activates Nrf2 and protects from acetaminophen hepatotoxicity via Nrf2-dependent and Nrf2-independent processes. Biochem Pharmacol 2009; 77: 1273-1282
29. Wang X, Ye XL, Liu R, Chen HL, Bai H, Liang X, Zhang XD, Wang Z, Li WL, Hai CX. Antioxidant activities of oleanolic acid in vitro: possible role of Nrf2 and MAP kinases. Chem Biol Interact 2010; 184: 328-337
30. Zhu Z, Wilson AT, Mathahs MM, Wen F, Brown KE, Luxon BA, Schmidt WN. Heme oxygenase-1 suppresses hepatitis C virus replication and increases resistance of hepatocytes to oxidant injury. Hepatology 2008; 48: 1430-1439
31. Roller J, Laschke MW, Scheuer C, Menger MD. Heme oxygenase (HO)-1 protects from lipopolysaccharide (LPS)-mediated liver injury by inhibition of hepatic leukocyte accumulation and improvement of microvascular perfusion. Langenbecks Arch Surg 2010; 395: 387-394
32. Immenschuh S, Baumgart-Vogt E, Mueller S. Heme oxygenase-1 and iron in liver inflammation: a complex alliance. Curr Drug Targets 2010; 11: 1541-1550
33. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845
34. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873
35. Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A, Kitamura N, Toda K, Kaneko T, Horie Y, Han JY, Kato S, Shimoda M, Oike Y, Tomizawa M, Makino S, Ohkura T, Saito H, Kumagai N, Nagata H, Ishii H, Hibi T. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 2006; 55: 415-424
36. Suzuki A, Lindor K, St Saver J, Lymp J, Mendes F, Muto A, Okada T, Angulo P. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 2005; 43: 1060-1066
37. Omagari K, Morikawa S, Nagaoka S, Sadakane Y, Sato M, Hamasaki M, Kato S, Masuda J, Osabe M, Kadota T, Sera K. Predictive factors for the development or regression of Fatty liver in Japanese adults. J Clin Biochem Nutr 2009; 45: 56-67
38. Rautou PE, Mansouri A, Lebrec D, Durand F, Valla D, Moreau R. Autophagy in liver diseases. J Hepatol 2010; 53: 1123-1134
39. Amir M, Czaja MJ. Autophagy in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol 2011; 5: 159-166
40. Wu J, Zhao MY, Zheng H, Zhang H, Jiang Y. Pentoxifylline alleviates high-fat diet-induced non-alcoholic steatohepatitis and early atherosclerosis in rats by inhibiting AGE and RAGE expression. Acta Pharmacol Sin 2010; 31: 1367-1375
41. Liu J, Liu Y, Klaassen CD. Protective effect of oleanolic acid against chemical-induced acute necrotic liver injury in mice. Zhongguo Yao Li Xue Bao 1995; 16: 97-102
42. Liu Y, Kreppel H, Liu J, Choudhuri S, Klaassen CD. Oleanolic acid protects against cadmium hepatotoxicity by inducing metallothionein. J Pharmacol Exp Ther 1993; 266: 400-406
43. Liu J, Liu Y, Madhu C, Klaassen CD. Protective effects of oleanolic acid on acetaminophen-induced hepatotoxicity in mice. J Pharmacol Exp Ther 1993; 266: 1607-1613
44. Tang XH, Gao J, Fang F, Chen J, Xu LZ, Zhao XN, Xu Q. Hepatoprotection of oleanolic acid is related to its inhibition on mitochondrial permeability transition. Am J Chin Med 2005; 33: 627-637
45. Saravanan R, Viswanathan P, Pugalendi KV. Protective effect of ursolic acid on ethanol-mediated experimental liver damage in rats. Life Sci 2006; 78: 713-718
46. Martin-Aragón S, de las Heras B, Sanchez-Reus MI, Benedi J. Pharmacological modification of endogenous antioxidant enzymes by ursolic acid on tetrachloride-induced liver damage in rats and primary cultures of rat hepatocytes. Exp Toxicol Pathol 2001; 53: 199-206
47. Sunitha S, Nagaraj M, Varalakshmi P. Hepatoprotective effect of lupeol and lupeol linoleate on tissue antioxidant defence system in cadmium-induced hepatotoxicity in rats. Fitoterapia 2001; 72: 516-523